AG
STOK icon

Algert Global’s Stoke Therapeutics STOK Stock Holding History

Algert Global’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,540
Closed -$66K – 1265
2023
Q4 		$66K Sell
12,540
-4,010
-24% -$17.1K ﹤0.01% 1096
2023
Q3 		$65K Sell
16,550
-18,298
-53% -$120K ﹤0.01% 1057
2023
Q2 		$370K Hold
34,848
– – 0.02% 871
2023
Q1 		$290K Buy
34,848
+24,748
+245% +$223K 0.01% 954
2022
Q4 		$93K Sell
10,100
-69,848
-87% -$726K 0.01% 1079
2022
Q3 		$1.03M Buy
+79,948
New +$1.27M 0.06% 532

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Algert Global's STOK Position: Q1 2024 in Review

Algert Global sold out of Stoke Therapeutics (STOK) in Q1 2024, closing a stake of 12,540 shares — an estimated $66K sold.

Algert Global first reported a position in STOK in Q3 2022 and held it in 6 quarters. The position peaked at $1.03M in Q3 2022. 103 funds tracked by Wall St. Rank hold STOK as of Q1 2024.

  • Algert Global reported no remaining Stoke Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Algert Global sold 12,540 Stoke Therapeutics shares in Q1 2024, an estimated $66K.
  • Algert Global first reported a position in Stoke Therapeutics in Q3 2022 and held it in 6 quarters.
  • Algert Global's Stoke Therapeutics position peaked at $1.03M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2024.

Based on Algert Global's 13F filing for Q1 2024, filed 15 May 2024.